Company: LIMN
Filing Date: 2025-06-24
Form Type: S-1
Source: 0001410578-25-001432
Chunk: 8

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: S-1
Chunk 8
---
 develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47 products (collectively, “CD47 Products”), from Curis Biotech Holdings LLC, the parent company of Valetudo Therapeutics LLC (“Valetudo”), a related party of the Company.

On April 30, 2025, the Company completed the Business Combination contemplated by the Business Combination Agreement, dated as of November 30, 2022 (as amended), by and among Iris, ParentCo, Liminatus Merger Sub, SPAC Merger Sub and Liminatus.

Our principal executive offices are located at 6 Centerpointe Drive #625, La Palma, California 90623 and our telephone number is (213) 273-5453.

Completion of the Mergers

As previously reported on the Current Report on Form 8-K filed by Iris with the SEC on March 10, 2025, Iris held a special meeting of stockholders on March 4, 2025 (the “Special Meeting”). At the Special Meeting, Iris’ stockholders approved the proposals outlined in the proxy statement/prospectus, including, among other things, adoption of the Business Combination Agreement and approval of the transactions contemplated by the Business Combination Agreement, including: (a) the merger of Liminatus Merger Sub with and into Liminatus, with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of ParentCo, and (b) simultaneously with the Liminatus Merger, the merger of SPAC Merger Sub with and into Iris, with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of ParentCo, and the issuance of the Company’s securities as consideration thereunder.

On the Closing Date, (i) Iris effected the SPAC Merger by filing a certificate of merger with the Secretary of State of the State of Delaware in accordance with the applicable provisions of the DGCL, and (ii) the Company effected the Liminatus Merger by filing a certificate of merger with the Secretary of State of the State of Delaware in accordance with the applicable provisions of the Delaware Limited Liability Company Act, with each of the Mergers being consummated and effective simultaneously as of April 30, 2025.

In connection with the Business Combination, the Company filed an amended and restated certificate of incorporation, which, among other things, changed the Company’s name to “Liminatus Pharma,